Evaluation of perioperative administration of sivelestat sodium hydrate in patients underwent pancreatoduodenectomy

Evaluation of perioperative administration of sivelestat sodium hydrate in patients underwent pancreatoduodenectomy - Perioperative administration of sivelestat in patients underwent PD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001249

Enrollment

Registered

2008-07-21

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periampullary disease requiring panceatoduodenectomy

Interventions

Perioperative administration of sivelestat sodium hydrate Perioperative non-administration of sivelestat sodium hydrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: 1.Previous history of hypersensitibity to sivelestat sodium hydrate 2.Increase in left atrial pressure 3.Multiple organ dysfunction 4.Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Incidence of acute lung injury	—

Secondary

Measure	Time frame
Incidence of postoperative complication	—

Countries

Japan

Contacts

Public ContactFumihiko Miura

Teikyo University School of Medicine Department of Surgery

f-miura@med.teikyo-u.ac.jp03-3964-1228

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026